Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus price objective of $8.00 for the company and are expecting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also assigned Pieris Pharmaceuticals an industry rank of 92 out of 265 based on the ratings given to its competitors.

Separately, Roth Capital restated a “buy” rating and set a $6.00 price target on shares of Pieris Pharmaceuticals in a research note on Friday, August 5th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/zacks-pieris-pharmaceuticals-inc-nasdaqpirs-receives-consensus-recommendation-of-strong-buy-from-analysts.html

Several hedge funds and other institutional investors have recently made changes to their positions in PIRS. Sabby Management LLC raised its position in shares of Pieris Pharmaceuticals by 132.7% in the first quarter. Sabby Management LLC now owns 175,000 shares of the company’s stock valued at $333,000 after buying an additional 99,792 shares during the period. BVF Inc. IL purchased a new position in Pieris Pharmaceuticals during the second quarter worth about $389,000. Lombard Odier Asset Management USA Corp raised its position in Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock worth $5,099,000 after buying an additional 533,965 shares during the last quarter. Frontier Wealth Management LLC purchased a new position in Pieris Pharmaceuticals during the second quarter worth about $137,000. Finally, BlackRock Fund Advisors purchased a new position in Pieris Pharmaceuticals during the second quarter worth about $113,000. Institutional investors own 45.79% of the company’s stock.

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) traded up 1.90% during midday trading on Tuesday, hitting $1.61. 120,252 shares of the stock were exchanged. The stock’s 50 day moving average is $1.64 and its 200 day moving average is $1.80. Pieris Pharmaceuticals has a 12-month low of $1.26 and a 12-month high of $3.08. The firm’s market cap is $69.32 million.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. The firm had revenue of $1.07 million for the quarter. Pieris Pharmaceuticals had a negative net margin of 346.01% and a negative return on equity of 52.21%. On average, equities research analysts forecast that Pieris Pharmaceuticals will post ($0.55) earnings per share for the current fiscal year.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

5 Day Chart for NASDAQ:PIRS

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.